Obamacare Causes Merck, Glaxo to End Co-Pay Assistance
This article is for subscribers only.
Abandoning a long-held industry tradition, GlaxoSmithKline Plc and Merck & Co. won’t help low-income Obamacare patients pay for their high-priced drugs.
The drugmakers say they won’t provide the assistance until the government decides whether programs overseen by the U.S. health-care act are subject to federal laws banning kickbacks that steer business to companies. So far, U.S. agencies have sent mixed messages on the issue, industry officials said.